Vanda Pharmaceuticals (VNDA) : 3 brokerage houses believe that Vanda Pharmaceuticals (VNDA) is a Strong Buy at current levels. Zacks Investment Research suggests a Buy with a rank of 2.The median of all the 3 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.
Vanda Pharmaceuticals (VNDA) : The highest level Vanda Pharmaceuticals (VNDA) is projected to reach is $20 for the short term and the lowest estimate is at $15. The consolidated price target from 3 rating analysts who initiate coverage on the stock is $17 and the possibility the share price can swing is $2.65.
For the current week, the company shares have a recommendation consensus of Buy. Vanda Pharmaceuticals (NASDAQ:VNDA): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $12.27 and $12.22 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $13.28. The buying momentum continued till the end and the stock did not give up its gains. It closed at $12.96, notching a gain of 5.71% for the day. The total traded volume was 1,404,966 . The stock had closed at $12.26 on the previous day.
In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (SVP, CFO, Sec & Treasurer) of Vanda Pharmaceuticals Inc., Kelly James Patrick had sold 9,564 shares worth of $85,693 in a transaction dated January 4, 2016. In this transaction, 9,564 shares were sold at $8.96 per share.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Companys product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. HETLIOZ (tasimelteon) is a product for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) for which a New Drug Application (NDA) was approved by the United States Food and Drug Administration (FDA). Fanapt (iloperidone) is a product for the treatment of schizophrenia. Tradipitant (VLY-686) is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is under clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.